摘要
循环肿瘤DNA(circulating tumor DNA,ctDNA)已经应用于监测转移性非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗。近来研究者开始关注ctDNA预测早期NSCLC患者根治术后微小残留病灶(minimal residual disease,MRD)的价值。全文总结目前常用的ctDNA检测方法,并介绍了其在早期肺癌术后评估MRD和复发预警方面的应用进展。
Circulating tumor DNA(ctDNA) has been widely used in monitoring efficacy of targeted therapy for metastatic non-small-cell lung cancer(NSCLC). Recent researches are focusing on the value of ctDNA in predicting minimal residual disease(MRD) of patients with early-stage cancer after treatment. This article reviews the techniques for detecting ctDNA and its application in monitoring MRD and recurrence in patients with early-stage NSCLC after radical resection.
作者
姚舒洋
张毅
YAO Shu-yang;ZHANG Yi(Xuanwu Hospital Capital Medical University,Beijing 100053,China)
出处
《肿瘤学杂志》
CAS
2023年第1期66-70,共5页
Journal of Chinese Oncology
基金
2021年吴阶平医学基金会资助(320.6750.2021-23-4)。
关键词
非小细胞肺癌
微小残留病灶
循环肿瘤DNA
液体活检
non-small cell lung cancer
minimal residual disease
circulating tumor DNA
liquid biopsy